NEWARK, Calif., May 11, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced financial results and a corporate update for the quarter ended March 31, 2017.
“Our primary therapeutic focus at CymaBay today is in liver disease. We believe we are well positioned to advance our lead development candidate, seladelpar, for patients with primary biliary cholangitis (PBC), and to subsequently implement a broader strategy to expand the development of seladelpar in other liver diseases, including nonalcoholic steatohepatitis (NASH),” said Sujal Shah, Interim President and Chief Executive Officer of CymaBay Therapeutics. “Our second Phase 2 dose-ranging study investigating seladelpar in PBC is progressing well, and we look forward to announcing key interim data expected in the third quarter. We view the announcement of these data as a significant milestone for the company and a key event to trigger planning and launch of a Phase 3 program for seladelpar in PBC.”
